Your browser doesn't support javascript.
loading
Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis.
Shields, Shannon D; Butt, Richard P; Dib-Hajj, Sulayman D; Waxman, Stephen G.
Afiliación
  • Shields SD; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, Connecticut, United States of America; Rehabilitation Research Center, Veterans' Affairs Connecticut Healthcare System, West Haven, Connecticut, United States of America.
  • Butt RP; Neusentis UK, Pfizer Global R&D, Cambridge, United Kingdom.
  • Dib-Hajj SD; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, Connecticut, United States of America; Rehabilitation Research Center, Veterans' Affairs Connecticut Healthcare System, West Haven, Connecticut, United States of America.
  • Waxman SG; Department of Neurology and Center for Neuroscience and Regeneration Research, Yale University School of Medicine, New Haven, Connecticut, United States of America; Rehabilitation Research Center, Veterans' Affairs Connecticut Healthcare System, West Haven, Connecticut, United States of America.
PLoS One ; 10(3): e0119067, 2015.
Article en En | MEDLINE | ID: mdl-25747279

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células de Purkinje / Canal de Sodio Activado por Voltaje NAV1.8 / Bloqueadores del Canal de Sodio Activado por Voltaje / Esclerosis Múltiple Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2015 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Células de Purkinje / Canal de Sodio Activado por Voltaje NAV1.8 / Bloqueadores del Canal de Sodio Activado por Voltaje / Esclerosis Múltiple Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2015 Tipo del documento: Article